Overview

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Status:
Not yet recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

This is an open-label randomised multicenter clinical study to investigate efficacy, safety, and immunogenicity of the drug products: Insulin Glargine biosimilar ® Log-G and its reference Lantus® in type 2 diabetes mellitus patients

Phase:

Phase 2

Details

Lead Sponsor:

Indonesia University

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc